Non-Insulin Dependent Diabetes in Children and Adolescents: The Therapeutic Challenge

Data are presented comparing non-insulin dependent diabetes mellitus (NIDDM) and insulin dependent diabetes mellitus (IDDM) in youth. Children and adolescents with NIDDM were predominantly Mexican-American, presented less frequently in ketoacidosis, had a greater frequency of family history of diabetes, had higher BMIs (27.4 vs 16.6 kg/m2), and had higher frequency of acanthosis nigricans (67% vs 1.2%). Logistical, social, and cultural challenges facing the physician treating children and adolescents with NIDDM are discussed, and treatment options for NIDDM in youth are briefly reviewed. Clin Pediatr. 1998;37:103-110

[1]  S. Haffner,et al.  Type II Diabetes Mellitus and Polymorphism of Insulin-Receptor Gene in Mexican Americans , 1989, Diabetes.

[2]  G. Bray,et al.  Multicenter, placebo-controlled trial comparing acarbose (BAY g 5421) with placebo, tolbutamide, and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. , 1995, The American journal of medicine.

[3]  B. Hoogwerf,et al.  Nutrition Principles for the Management off Diabetes and Related Complications , 1994, Diabetes Care.

[4]  I. Campbell,et al.  One year comparative trial of metformin and glipizide in type 2 diabetes mellitus. , 1994, Diabete & metabolisme.

[5]  Lucis Oj.  The status of metformin in Canada , 1983 .

[6]  J. Gerich.  Oral hypoglycemic agents. , 1989, The New England journal of medicine.

[7]  J. McGill,et al.  Reduction of Glycosylated Hemoglobin and Postprandial Hyperglycemia by Acarbose in Patients With NIDDM: A placebo-controlled dose-comparison study , 1995, Diabetes Care.

[8]  L. Groop,et al.  secondary Failure to Treatment with Oral Antidiabetic Agents in Non-insulin-dependent Diabetes , 1986, Diabetes Care.

[9]  K. Polonsky.  The β-Cell in Diabetes: From Molecular Genetics to Clinical Research , 1995, Diabetes.

[10]  J. Caro.  Clinical review 26: Insulin resistance in obese and nonobese man. , 1991, The Journal of clinical endocrinology and metabolism.

[11]  M. Harris,et al.  Prevalence of Adult-Onset IDDM in the U.S. Population , 1994, Diabetes Care.

[12]  P. Marchetti,et al.  Pharmacokinetic-Pharmacodynamic Relationships of Oral Hypoglycaemic Agents , 1989, Clinical pharmacokinetics.

[13]  D. McTavish,et al.  Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus. , 1993, Drugs.

[14]  E. Perez-stable,et al.  Prevalence of Diabetes in Mexican Americans, Cubans, and Puerto Ricans From the Hispanic Health and Nutrition Examination Survey, 1982–1984 , 1991, Diabetes Care.

[15]  R. Henry,et al.  Intensive Conventional Insulin Therapy for Type II Diabetes: Metabolic effects during a 6-mo outpatient trial , 1993, Diabetes Care.

[16]  S. Genuth.  Insulin Use in NIDDM , 1990, Diabetes Care.

[17]  J. Clement,et al.  Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. , 1995, Science.

[18]  G. Reaven.  Banting lecture 1988. Role of insulin resistance in human disease. , 1988, Diabetes.

[19]  P. Bennett,et al.  Prevalence of Diabetes and Impaired Glucose Tolerance and Plasma Glucose Levels in U.S. Population Aged 20–74 Yr , 1987, Diabetes.

[20]  Y. Iwamoto,et al.  Effect of New Oral Antidiabetic Agent CS-045 on Glucose Tolerance and Insulin Secretion in Patients with NIDDM , 1991, Diabetes Care.

[21]  R. DeFronzo,et al.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. , 1995, The New England journal of medicine.

[22]  F. Nuttall,et al.  Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trial , 1995, Diabetes Care.

[23]  M. Riddle.  Evening Insulin Strategy , 1990, Diabetes Care.

[24]  R. Holman,et al.  Insulin Use in NIDDM: Rationale Based on Pathophysiology of Disease , 1990, Diabetes Care.

[25]  J. A. Hunt,et al.  The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus , 1994 .

[26]  J. Relethford,et al.  Prevalence of Diabetes in Mexican Americans: Relationship to Percent of Gene Pool Derived from Native American Sources , 1984, Diabetes.

[27]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[28]  K. Polonsky.  The β-Cell in Diabetes: From Molecular Genetics to Clinical Research , 1995, Diabetes.

[29]  O. J. Lucis.  The status of metformin in Canada. , 1983, Canadian Medical Association journal.

[30]  J. Olefsky,et al.  Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes , 1996, Diabetes.

[31]  Insulin-Sensitive and Insulin-Resistant Variants in NIDDM , 1989, Diabetes.

[32]  T. Wolever,et al.  Nibbling versus gorging: metabolic advantages of increased meal frequency. , 1989, The New England journal of medicine.

[33]  G. Reaven.  Role of Insulin Resistance in Human Disease , 1988, Diabetes.

[34]  J. Olefsky,et al.  Metabolic Effects of New Oral Hypoglycemic Agent CS-045 in NIDDM Subjects , 1992, Diabetes Care.

[35]  S. Fajans.  Scope and Heterogeneous Nature of MODY , 1990, Diabetes Care.

[36]  G Dailey,et al.  Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. , 1995, The New England journal of medicine.

[37]  H. Bischoff.  Pharmacology of alpha-glucosidase inhibition. , 1994, European journal of clinical investigation.

[38]  T. Wolever,et al.  Metabolic effects of reducing rate of glucose ingestion by single bolus versus continuous sipping. , 1990, Diabetes.

[39]  J. Weaver.  Oral Antidiabetic Agents , 1959, British medical journal.

[40]  H. Neil,et al.  Sulphonylureas and hypoglycaemia , 1988, British medical journal.

[41]  R. Vigneri,et al.  Role of metformin in treatment of diabetes mellitus , 1987, Diabetes Care.

[42]  S. Genuth,et al.  Diabetes Control and Complications Trial (DCCT): Results of Feasibility Study. The DCCT Research Group , 1987, Diabetes Care.

[43]  C. Bogardus.  Insulin Resistance in the Pathogenesis of NIDDM in Pima Indians , 1993, Diabetes Care.

[44]  M. Harris.  Epidemiological Correlates of NIDDM in Hispanics, Whites, and Blacks in the u.s. Population , 1991, Diabetes Care.

[45]  W. Duckworth,et al.  Effect of chronic sulfonylurea therapy on plasma insulin and proinsulin levels. , 1972, The Journal of clinical endocrinology and metabolism.

[46]  H. Bischoff.  Pharmacology of α-glucosidase inhibition , 1994 .

[47]  J. A. Scarlett,et al.  The Acute and Chronic Effects of Sulfonylurea Therapy in Type II Diabetic Subjects , 1984, Diabetes.